Not available
Quote | Mesabi Trust (NYSE:MSB)
Last: | $17.26 |
---|---|
Change Percent: | 0.98% |
Open: | $17.1 |
Close: | $17.26 |
High: | $17.31 |
Low: | $16.98 |
Volume: | 20,107 |
Last Trade Date Time: | 04/25/2024 03:00:00 am |
News | Mesabi Trust (NYSE:MSB)
Bank of Hawaii Corporation (BOH) is expected to report $0.92 for Q1 2024 Brown & Brown Inc. (BRO) is expected to report $1.07 for Q1 2024 Independent Bank Group Inc (IBTX) is expected to report $0.57 for Q1 2024 Burnham Holdings Inc - Class A (BURCA) is expected to report for Q1 2...
2024-04-17 08:35:02 ET More on Mesabi Trust Mesabi Trust: Full Production Is Back Despite Cleveland-Cliffs' Ambitions Dividend scorecard for Mesabi Trust Financial information for Mesabi Trust Read the full article on Seeking Alpha For further details...
Message Board Posts | Mesabi Trust (NYSE:MSB)
Subject | By | Source | When |
---|---|---|---|
Northshore Mining on Iron Range open again after | Enterprising Investor | investorshub | 04/26/2023 12:43:24 PM |
ValueWorks LLC beneficially owns 806,437 shares (4/24/23) | Enterprising Investor | investorshub | 04/25/2023 9:28:46 AM |
Horizon Kinetics Asset Management LLC beneficially owns 2,684,726 | Enterprising Investor | investorshub | 04/25/2023 9:26:29 AM |
Form 10-K (4/24/23) | Enterprising Investor | investorshub | 04/25/2023 9:24:02 AM |
Mesabi Trust Press Release (4/14/23) | Enterprising Investor | investorshub | 04/21/2023 12:29:27 AM |
News, Short Squeeze, Breakout and More Instantly...
Bank of Hawaii Corporation (BOH) is expected to report $0.92 for Q1 2024 Brown & Brown Inc. (BRO) is expected to report $1.07 for Q1 2024 Independent Bank Group Inc (IBTX) is expected to report $0.57 for Q1 2024 Burnham Holdings Inc - Class A (BURCA) is expected to report for Q1 2...
2024-04-03 09:48:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
NEW YORK, March 25, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that U.S. FDA has informed the company that following additional consideration the available clinical data from its Phas...